Literature DB >> 35399173

Pan-cancer Bioinformatics Analysis of the Double-edged Role of Hypoxia-inducible Factor 1α (HIF-1α) in Human Cancer.

R U Li1, Kang Tang2, Qian Li3.   

Abstract

Background/Aim: Despite the emergence of cellular, animal, and clinical-based evidence demonstrating a link between hypoxia-inducible factor-1α (HIF-1α) and malignancy, the comprehensive assessment of HIF-1α in pan-cancer patients remains unclear, particularly regarding HIF-1α expression and its association with immune infiltration and immune checkpoint. The present study aimed to investigate the role of HIF-1α expression in various types of malignancies through bioinformatics analysis. Materials and
Methods: We investigated the expression and prognostic value of HIF-1α in pan-cancer based on the TCGA (The Cancer Genome Atlas) dataset. The abundance of immune infiltration was estimated by xCell immune deconvolution methods. We investigated the relationship of HIF-1α expression with immune infiltration and immune checkpoint gene expression, with a focus on gastric adenocarcinoma (STAD) and lung squamous cell carcinoma (LUSC).
Results: HIF-1α expression had different effects on the prognosis of various cancers. In contrast to the protective effect of HIF-1α expression in LUSC, high levels of HIF-1α expression played a detrimental role in the survival of STAD patients. There was a significant positive correlation between HIF-1α expression and immune infiltration in STAD patients, including regulatory T-cells (Tregs), T-cell CD4+ Th2, neutrophils, M1 and M2 macrophages. In addition, immune checkpoint molecules showed different HIF-1α-related profiles in various carcinomas.
Conclusion: A relatively comprehensive view of the oncogenic role of HIF-1α in various tumors based on a pan-cancer analysis is provided in this study. HIF-1α may be considered a poor prognostic biomarker for STAD and, moreover, it may be involved in regulating tumor immune infiltration. Copyright 2022, International Institute of Anticancer Research.

Entities:  

Keywords:  HIF-1α; Hypoxia; cancer prognosis; immune checkpoint; immune infiltration

Year:  2022        PMID: 35399173      PMCID: PMC8962818          DOI: 10.21873/cdp.10104

Source DB:  PubMed          Journal:  Cancer Diagn Progn        ISSN: 2732-7787


  43 in total

Review 1.  Mechanisms Controlling PD-L1 Expression in Cancer.

Authors:  Jong-Ho Cha; Li-Chuan Chan; Chia-Wei Li; Jennifer L Hsu; Mien-Chie Hung
Journal:  Mol Cell       Date:  2019-10-24       Impact factor: 17.970

Review 2.  Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.

Authors:  Elisa Ruffo; Richard C Wu; Tullia C Bruno; Creg J Workman; Dario A A Vignali
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

3.  The angiogenic switch leads to a metabolic shift in human glioblastoma.

Authors:  Krishna M Talasila; Gro V Røsland; Hanne R Hagland; Eskil Eskilsson; Irene H Flønes; Sabrina Fritah; Francisco Azuaje; Nadia Atai; Patrick N Harter; Michel Mittelbronn; Michael Andersen; Justin V Joseph; Jubayer Al Hossain; Laurent Vallar; Cornelis J F van Noorden; Simone P Niclou; Frits Thorsen; Karl Johan Tronstad; Charalampos Tzoulis; Rolf Bjerkvig; Hrvoje Miletic
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

4.  HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.

Authors:  Zhen Song; Tengfei Liu; Jing Chen; Chao Ge; Fangyu Zhao; Miaoxin Zhu; Taoyang Chen; Ying Cui; Hua Tian; Ming Yao; Jinjun Li; Hong Li
Journal:  Cancer Lett       Date:  2019-06-24       Impact factor: 8.679

Review 5.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

Review 6.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Authors:  Suzanne L Topalian; Janis M Taube; Robert A Anders; Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

Review 7.  Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.

Authors:  S K Daniel; K M Sullivan; K P Labadie; V G Pillarisetty
Journal:  Clin Transl Med       Date:  2019-04-01

8.  Pancancer survival analysis of cancer hallmark genes.

Authors:  Ádám Nagy; Gyöngyi Munkácsy; Balázs Győrffy
Journal:  Sci Rep       Date:  2021-03-15       Impact factor: 4.379

Review 9.  Follicular Helper T Cells.

Authors:  Carola G Vinuesa; Michelle A Linterman; Di Yu; Ian C M MacLennan
Journal:  Annu Rev Immunol       Date:  2016-02-22       Impact factor: 28.527

10.  ANXA2 promotes esophageal cancer progression by activating MYC-HIF1A-VEGF axis.

Authors:  Sai Ma; Chen-Chen Lu; Li-Yan Yang; Juan-Juan Wang; Bo-Shi Wang; Hong-Qing Cai; Jia-Jie Hao; Xin Xu; Yan Cai; Yu Zhang; Ming-Rong Wang
Journal:  J Exp Clin Cancer Res       Date:  2018-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.